Fox Run Management’s Filana Therapeutics FLNA Stock Holding History

Fox Run Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6,257	Closed	-$281K	–	430
2021 Q1	$281K	Buy	+6,257	New	+$246K	0.51%	85

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Fox Run Management's FLNA Position: Q2 2021 in Review

Fox Run Management sold out of Filana Therapeutics (FLNA) in Q2 2021, closing a stake of 6,257 shares — an estimated $281K sold.

Fox Run Management first reported a position in FLNA in Q1 2021 and held it in 1 quarter. The position peaked at $281K in Q1 2021. 169 funds tracked by Wall St. Rank hold FLNA as of Q2 2021.

Fox Run Management reported no remaining Filana Therapeutics position as of Q2 2021 after selling out during the quarter.
Fox Run Management sold 6,257 Filana Therapeutics shares in Q2 2021, an estimated $281K.
Fox Run Management first reported a position in Filana Therapeutics in Q1 2021 and held it in 1 quarter.
Fox Run Management's Filana Therapeutics position peaked at $281K in Q1 2021.
169 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2021.

Based on Fox Run Management's 13F filing for Q2 2021, filed 5 Aug 2021.